Enema for rectal application

Abstract

Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat inflammatory bowel disease, or to prevent a relapse. The enema for rectal application containing budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 6 weeks in order to treat inflammatory bowel disease, or to prevent a relapse; the enema for rectal application described above, in which a dose of budesonide is 2.0 mg per dose; the enema for rectal application according to any one of the above, which is taken in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse; the enema for rectal application according to any one of the above, which has a foamy shape or a liquid shape.

1 . An enema for rectal application comprising budesonide as an active ingredient, wherein 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 6 weeks in order to treat inflammatory bowel disease, or to prevent a relapse. 
     
     
         2 . The enema for rectal application according to  claim 1 , wherein the dose of budesonide is 2 mg per dose. 
     
     
         3 . The enema for rectal application according to  claim 1 , wherein the enema for rectal application is administered in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse. 
     
     
         4 . The enema for rectal application according to  claim 1 , wherein the enema for rectal application has a foamy shape or a liquid shape. 
     
     
         5 . A package of an enema for rectal application, wherein the enema for rectal application according to  claim 1  containing 1.5 to 2.5 mg of budesonide per dose can be administered 14 times. 
     
     
         6 . A manufacturing method of a package of an enema for rectal application, wherein the enema for rectal application according to  claim 1  is adjusted such that the enema for rectal application containing 1.5 to 2.5 mg of budesonide per dose can be administered 14 times. 
     
     
         7 . The enema for rectal application according to  claim 2 , wherein the enema for rectal application is administered in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse. 
     
     
         8 . The enema for rectal application according to  claim 2 , wherein the enema for rectal application has a foamy shape or a liquid shape. 
     
     
         9 . The enema for rectal application according to  claim 3 , wherein the enema for rectal application has a foamy shape or a liquid shape. 
     
     
         10 . A package of an enema for rectal application, wherein the enema for rectal application according to  claim 2  containing 1.5 to 2.5 mg of budesonide per dose can be administered 14 times. 
     
     
         11 . A package of an enema for rectal application, wherein the enema for rectal application according to  claim 3  containing 1.5 to 2.5 mg of budesonide per dose can be administered 14 times. 
     
     
         12 . A package of an enema for rectal application, wherein the enema for rectal application according to  claim 4  containing 1.5 to 2.5 mg of budesonide per dose can be administered 14 times. 
     
     
         13 . A manufacturing method of a package of an enema for rectal application, wherein the enema for rectal application according to  claim 2  is adjusted such that the enema for rectal application containing 1.5 to 2.5 mg of budesonide per dose can be administered 14 times. 
     
     
         14 . A manufacturing method of a package of an enema for rectal application, wherein the enema for rectal application according to  claim 3  is adjusted such that the enema for rectal application containing 1.5 to 2.5 mg of budesonide per dose can be administered 14 times. 
     
     
         15 . A manufacturing method of a package of an enema for rectal application, wherein the enema for rectal application according to  claim 4  is adjusted such that the enema for rectal application containing 1.5 to 2.5 mg of budesonide per dose can be administered 14 times.